- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02615340
Melatonin for Prevention of Delirium in Critically Ill Patients (MELLOW-1)
Feasibility of Melatonin for Prevention of Delirium in Critically Ill Patients: a Multi-centre, Randomized, Placebo-controlled Study.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The available evidence indicates melatonin may decrease the incidence of delirium in non-critically ill patient populations; however, trials in the critically ill are lacking. The investigators hypothesize that melatonin, administered on a scheduled nightly basis during ICU admission, will be efficacious and safe for the prevention of delirium in critically ill adults. The null hypothesis is that there is no difference in delirium incidence between placebo and melatonin. Prior to conducting an adequately powered multi-centre, blinded randomized, placebo-controlled trial in critically ill patients, there is a need for a better understanding of melatonin pharmacokinetics (PK) in critically ill patients. This will help to determine appropriate dosing, drug administration issues (specifically protocol adherence), adverse drug effects, and recruitment rates based on inclusion and exclusion criteria.
The specific aim is to conduct a phase II triple blind, placebo-controlled randomized trial comparing two doses of melatonin (low dose = 0.5 mg and high dose = 2.0 mg) to assess the feasibility of a future full-scale RCT. Feasibility of the larger trial will be based on protocol adherence and participant recruitment rates. Data on PK properties of melatonin will be assessed to determine dosing for future studies of melatonin for delirium prevention in the critically ill.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G1X5
- Rekrutierung
- Mount Sinai Hospital
-
Kontakt:
- Lisa Burry, PharmD
- E-Mail: lisa.burry@sinaihealthsystem.ca
-
Hauptermittler:
- Lisa Burry
-
Toronto, Ontario, Kanada
- Rekrutierung
- Sunnybrook Health Sciences Centre
-
Kontakt:
- Damon Scales
- E-Mail: damon.scales@sunnybrook.ca
-
Hauptermittler:
- Damon Scales, MD PhD
-
Hauptermittler:
- Louise Rose, PhD
-
-
Quebec
-
Montréal, Quebec, Kanada
- Noch keine Rekrutierung
- Hopital du Sacre-Coeur
-
Kontakt:
- David Williamson
- E-Mail: david.williamson@umontreal.ca
-
Hauptermittler:
- David Williamson, PhD
-
Hauptermittler:
- Francis Bernard, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Critically ill patients ≥18 years of age
- Anticipated ICU stay of >48 hours
- Able to receive enteral administration of study drug (i.e. by mouth or any feeding tube = naso- or oro- or percutaneous gastric or post-pyloric feeding tube)
- Consent to participate.
Exclusion Criteria:
- ICU admission of >48 hours prior to screening
- Unable to assess for delirium (e.g. comatose defined as SAS 1 or 2 or either 'No Response' Score A or B on ICDSC, chemically paralyzed with neuromuscular blocking drugs)
- Screened delirium positive prior to randomization (ICDSC score ≥4 out of 8)
- Anticipated withdrawal in next 48 hours
- Known history of severe cognitive or neurodegenerative disease (e.g. dementia, Parkinson's disease) or severe structural brain injury (e.g. traumatic brain injury, intracranial hemorrhage) as the ICDSC assessment tool has not been validated in these patient populations
- Unable to communicate in English or French (Montreal site)
- Contraindications to receiving any enteral medication (defined as absolute contraindication to enteral nutrition such as gastrointestinal obstruction, perforation, recent upper GI surgery, no enteral access)
- Active seizures
- Known pregnancy
- Legal blindness
- Known allergy to melatonin
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Enteral melatonin 0.5 mg
Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
|
Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission.
The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water.
Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Andere Namen:
|
Aktiver Komparator: Enteral melatonin 2 mg
Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
|
Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission.
The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water.
Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
Andere Namen:
|
Placebo-Komparator: Enteral matched placebo
Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
|
Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission.
The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water.
Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Feasibility: Study adherence
Zeitfenster: 1 year
|
Investigators will calculate protocol adherence as the overall proportion of administered doses in the prescribed dose administration window (between 21:00 and to 23:59 hours) divided by total number of eligible study days.
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Feasibility: Trial recruitment
Zeitfenster: 1 year
|
Proportion of ICU patients screened that meet study inclusion criteria, the number of patients excluded and reasons for exclusion, and the consent rate of eligible participants.
|
1 year
|
Feasibility: Time in motion (minutes)
Zeitfenster: 1 year
|
Research coordinators at each site will capture the amount of time (minutes) taken to screen, consent, and enrol patients, complete study procedures, and collect data.
|
1 year
|
Pharmacokinetic: Peak melatonin concentration (Cmax)
Zeitfenster: 24 hours
|
Peak melatonin concentration. Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Time of peak melatonin concentration (Tmax)
Zeitfenster: 24 hours
|
Time of peak melatonin concentration (Tmax). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Morning melatonin concentration (C9AM)
Zeitfenster: 24 hours
|
Morning melatonin concentration (C9AM). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Melatonin half-life (T½)
Zeitfenster: 24 hours
|
Melatonin half-life (T½). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Mean apparent clearance (CL/F)
Zeitfenster: 24 hours
|
Mean apparent clearance (CL/F). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Mean apparent volume distribution (V/F)
Zeitfenster: 24 hours
|
Mean apparent volume distribution (V/F). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Pharmacokinetic: Area under the concentration-time curve (AUC)
Zeitfenster: 24 hours
|
Area under the concentration-time curve (AUC). Plasma melatonin concentrations measured by mass spectrometry. N=5 from each study arm of Mount Sinai Hospital site. On study day 1, eight blood samples (4 mL each) will be collected at the following intervals, from the time of first study drug dose to the following morning (time 0, 0.5, 1, 2, 4, 6, 8, 12 hours). |
24 hours
|
Clinical: Adverse events
Zeitfenster: 14 days
|
Adverse events reported by the participant, family, or treating team.
The following potential adverse effects will be collected: morning drowsiness (Sedation Agitation Scale (SAS) score <3 or patient's self report of drowsiness between 07:00h and 12:00h), headache, and vivid dreams.
|
14 days
|
Clinical: Delirium incidence
Zeitfenster: 14 days
|
Intensive Care Delirium Screening Checklist (ICDSC) administered daily.
Delirium defined as an ICDSC score ≥4.
|
14 days
|
Clinical: Delirium time to onset and duration (days)
Zeitfenster: 14 days
|
Time to onset of first ICDSC score ≥4, and number of days with ICDSC score ≥4.
|
14 days
|
Clinical: Sleep
Zeitfenster: 14 days
|
Richards Campbell Sleep Questionnaire (RCSQ) administered daily, where possible.
Patients with or without the assistance of their nurse will be asked to complete the questions of the RCSQ each morning.
Nurses will not complete the RCSQ if the patient is unable to verbalize, as poor correlation has been shown between patient and nursing scores.
|
14 days
|
Clinical: Duration of mechanical ventilation
Zeitfenster: ICU admission
|
Duration of mechanical ventilation (days)
|
ICU admission
|
Clinical: ICU length of stay
Zeitfenster: ICU admission
|
Duration of stay for index ICU admission (days)
|
ICU admission
|
Clinical: Hospital length of stay
Zeitfenster: 1 year
|
Duration of stay for admission involving trial enrolment (days)
|
1 year
|
Clinical: ICU mortality
Zeitfenster: 1 year
|
Number of deaths during index ICU admission
|
1 year
|
Clinical: Hospital mortality
Zeitfenster: 1 year
|
Number of deaths during hospital admission
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lisa Burry, PharmD, Mount Sinai Hospital
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Erkrankungen des Nervensystems
- Neurologische Manifestationen
- Verwirrtheit
- Neurobehaviorale Manifestationen
- Neurokognitive Störungen
- Delirium
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Depressiva des zentralen Nervensystems
- Schutzmittel
- Antioxidantien
- Melatonin
Andere Studien-ID-Nummern
- 4000145150
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Delirium
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicAbgeschlossenDelirium im Alter | Delirium gemischten Ursprungs | Demenz überlagertes Delirium | Delirium Verwirrter ZustandNorwegen
-
Johns Hopkins UniversityNational Institute on Aging (NIA)Aktiv, nicht rekrutierendDelirium | Delirium beim Auftauchen | Schwerhörigkeit | Hörverlust, Hochfrequenz | Hörverlust, sensorineural | Delirium, Ursache unbekannt | Hörverlust, bilateral | Hörbehinderung | Delirium im Alter | Delirium gemischten Ursprungs | Demenz überlagertes Delirium | Delirium Verwirrter Zustand | Delirium mit Demenz und andere BedingungenVereinigte Staaten
-
Universidad de SantanderUnbekanntDelirium gemischten Ursprungs | Hypoaktives Delirium | Hyperaktives DeliriumKolumbien
-
Imperial College Healthcare NHS TrustRekrutierungHerzchirugie | Intensivstation Delirium | Postoperatives DeliriumVereinigtes Königreich
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnbekanntDelirium | Delirium, Ursache unbekannt | Delirium gemischten Ursprungs | Delirium Verwirrter Zustand | Medikamenteninduziertes DelirIsrael
-
Azienda Ospedaliero-Universitaria di ParmaRekrutierungPostoperatives Delirium | Herzchirugie | Intensivstation DeliriumItalien
-
University of Southern CaliforniaRekrutierungDelirium | Nebenwirkungen der Behandlung | Moral | Delirium im Alter | Psych | Delirium gemischten Ursprungs | Delirium Verwirrter Zustand | Delirium, Sepsis assoziiertVereinigte Staaten
-
Indonesia UniversityNoch keine RekrutierungPostoperatives Delirium | Anästhesie | Postoperative Verwirrung | Neurologische Störung | Anästhesie Entstehung Delirium | Gas; Inhalation | Hypnotisch; Entzugszustand mit Delirium
-
Bruyere Research InstituteThe Ottawa Hospital; Foothills Medical Centre; Bruyère Continuing CareRekrutierungDelirium gemischten Ursprungs | Hyperaktives DeliriumKanada
-
Penn State UniversityBeth Israel Deaconess Medical Center; Mount Nittany Medical Center; Penn State...Noch keine RekrutierungDelirium | Delirium im Alter | Demenz überlagertes Delirium | Delirium mit Demenz
Klinische Studien zur Melatonin
-
Duquesne UniversityAbgeschlossen
-
Ain Shams UniversityAbgeschlossenZerebralparese | Wachstum | Nur Kinder | MelatoninÄgypten
-
Qazvin University Of Medical SciencesAbgeschlossenPostpartale Blutung bei Patienten mit KaiserschnittIran, Islamische Republik
-
University of MilanAbgeschlossenBioverfügbarkeitItalien
-
Assistance Publique - Hôpitaux de ParisBeendet
-
Providence Health & ServicesAbgeschlossenSchubförmig remittierende Multiple SkleroseVereinigte Staaten
-
Mayo ClinicRekrutierungParkinson Krankheit | Schnelle Augenbewegungs-SchlafverhaltensstörungVereinigte Staaten
-
Khon Kaen UniversityThailand Research Fund; Srinagarind Hospital, Khon Kaen University; Khon Kaen... und andere MitarbeiterAbgeschlossenKrebs im fortgeschrittenen StadiumThailand
-
Fayoum UniversityAbgeschlossenImpaktierter dritter BackenzahnÄgypten
-
Pharmavite LLCKGK Science Inc.Abgeschlossen